156 related articles for article (PubMed ID: 3111953)
1. Clinical evaluation of antithrombin III concentrate (BI 6.013) for disseminated intravascular coagulation in obstetrics. Well-controlled multicenter trial.
Maki M; Terao T; Ikenoue T; Takemura T; Sekiba K; Shirakawa K; Soma H
Gynecol Obstet Invest; 1987; 23(4):230-40. PubMed ID: 3111953
[TBL] [Abstract][Full Text] [Related]
2. Gabexate mesilate (FOY) therapy of disseminated intravascular coagulation due to sepsis.
Taenaka N; Shimada Y; Hirata T; Nishijima MK; Takezawa J; Yoshiya I; Kambayashi J
Crit Care Med; 1983 Sep; 11(9):735-8. PubMed ID: 6411432
[TBL] [Abstract][Full Text] [Related]
3. [Treatment of disseminated intravascular coagulation with proteinase inhibitor].
Okamoto K; Takeda S; Ohsato K
Nihon Rinsho; 1991 Sep; 49(9):2130-5. PubMed ID: 1960878
[No Abstract] [Full Text] [Related]
4. [Anticoagulant therapy in obstetrical disorders].
Murata M; Hayakawa M; Goto K; Isobe K; Matuura T; Hirano H; Higuchi M; Maki M
Rinsho Ketsueki; 1990 Jun; 31(6):763-8. PubMed ID: 2170703
[TBL] [Abstract][Full Text] [Related]
5. [Synthetic protease inhibitors in the treatment of disseminated intravascular coagulation].
Aramoto H; Saito H; Shigematsu H; Muto T
Nihon Rinsho; 1993 Jan; 51(1):93-8. PubMed ID: 8433532
[TBL] [Abstract][Full Text] [Related]
6. Survival from DIC following amniotic fluid embolism. Successful treatment with a serine proteinase inhibitor; FOY.
Taenaka N; Shimada Y; Kawai M; Yoshiya I; Kosaki G
Anaesthesia; 1981 Apr; 36(4):389-93. PubMed ID: 6787945
[TBL] [Abstract][Full Text] [Related]
7. Gabexate as a therapy for disseminated intravascular coagulation.
Umeki S; Adachi M; Watanabe M; Yaji S; Soejima R
Arch Intern Med; 1988 Jun; 148(6):1409-12. PubMed ID: 3132124
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effects of gabexate mesilate (FOY) on experimental DIC.
Isobe J
Adv Exp Med Biol; 1979; 120B():385-94. PubMed ID: 229708
[TBL] [Abstract][Full Text] [Related]
9. [Clinical trial of protease inhibitor in the treatment of fulminant hepatitis].
Yasunaga M; Mori K; Yamashita S; Okita K
Nihon Rinsho; 1991 Sep; 49(9):2120-4. PubMed ID: 1960877
[No Abstract] [Full Text] [Related]
10. Comparison of gabexate mesilate and nafamostat mesilate for disseminated intravascular coagulation associated with hematological malignancies.
Minakata D; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Umino K; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Ohmori T; Kanda Y
Int J Hematol; 2019 Feb; 109(2):141-146. PubMed ID: 30536180
[TBL] [Abstract][Full Text] [Related]
11. [Fundamental studies on the management of disseminated intravascular coagulation (DIC) with antithrombin III (AT-III) concentrate].
Gotoh K
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Apr; 37(4):571-80. PubMed ID: 3989338
[TBL] [Abstract][Full Text] [Related]
12. Disseminated intravascular coagulation with multiple arterial thromboses responding to antithrombin-III concentrate infusion.
Wisecarver JL; Haire WD
Thromb Res; 1989 Jun; 54(6):709-17. PubMed ID: 2781511
[TBL] [Abstract][Full Text] [Related]
13. Anticoagulation with a synthetic thrombin inhibitor after cardiovascular surgery and for treatment of disseminated intravascular coagulation.
Kumon K; Tanaka K; Nakajima N; Naito Y; Fujita T
Crit Care Med; 1984 Dec; 12(12):1039-43. PubMed ID: 6439471
[TBL] [Abstract][Full Text] [Related]
14. [Treatment of disseminated intravascular coagulation (DIC) or pre-DIC with gabexate mesilate (FOY)].
Wada H; Suzuki H; Mori Y; Deguchi A; Oukubo I; Tsuda M; Tanaka I; Deguchi K; Shirakawa S; Minami N
Nihon Gan Chiryo Gakkai Shi; 1988 Jan; 23(1):67-73. PubMed ID: 3132518
[No Abstract] [Full Text] [Related]
15. [Evaluation of FOY therapy for DIC or pre-DIC associated with neurosurgical disease].
Wakui K; Takemae T; Kobayashi S
No Shinkei Geka; 1990 Jul; 18(7):609-17. PubMed ID: 2118601
[TBL] [Abstract][Full Text] [Related]
16. Effects of antithrombin and gabexate mesilate on disseminated intravascular coagulation: a preliminary study.
Nishiyama T; Kohno Y; Koishi K
Am J Emerg Med; 2012 Sep; 30(7):1219-23. PubMed ID: 22204993
[TBL] [Abstract][Full Text] [Related]
17. [Preliminary study for the evaluation of the feasibility of a multicenter clinical trial for the evaluation of the therapeutic efficacy of an antithrombin III concentration (Immuno) in the intravascular coagulation syndrome].
Palareti G; Legnani C; Ludovici S; Maccaferri M
Haematologica; 1990; 75 Suppl 2():21-32. PubMed ID: 2201605
[No Abstract] [Full Text] [Related]
18. High dose of intravenous antithrombin III without heparin in the treatment of disseminated intravascular coagulation and organ failure in four children.
Fuse S; Tomita H; Yoshida M; Hori T; Igarashi C; Fujita S
Am J Hematol; 1996 Sep; 53(1):18-21. PubMed ID: 8813091
[TBL] [Abstract][Full Text] [Related]
19. Severe antithrombin III deficiency in a patient with pre-eclampsia. Observations on the effect of human AT III concentrate transfusion.
Büller HR; Weenink AH; Treffers PE; Kahlé LH; Otten HA; ten Cate JW
Scand J Haematol; 1980 Jul; 25(1):81-6. PubMed ID: 7444377
[TBL] [Abstract][Full Text] [Related]
20. Antithrombin III patterns in disseminated intravascular coagulation.
Bick RL; Bick MD; Fekete LF
Am J Clin Pathol; 1980 Apr; 73(4):577-83. PubMed ID: 7369182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
